Alexion, AstraZeneca Rare Disease, will present robust clinical and real-world data from its rare neurology portfolio at the American Academy of Neurology (AAN) Annual Meeting in San Diego, CA, 5 to 9 April 2025. The company will present 21 abstracts, including three oral presentations, across neuromyelitis optica spectrum disorder (NMOSD) and generalised myasthenia gravis (gMG).
Presentations will offer analyses of the CHAMPION-NMOSD and PREVENT trials as well as real-world data evaluating the long-term safety profile and efficacy of Ultomiris (ravulizumab) and Soliris (eculizumab) in NMOSD and gMG.
Christophe Hotermans, Senior Vice President, Head of Global Medical Affairs, Alexion, said: “At this year’s AAN, we continue to build on our legacy of innovation for people living with rare diseases by presenting new real-world and clinical evidence that highlight the transformational impact of Ultomiris and Soliris in the long-term treatment of NMOSD and gMG. This latest data will reinforce the sustained efficacy and safety profile of Ultomiris and Soliris, as well as the benefits of long-term treatment in these patient populations, offering meaningful insights to help improve patient care and deepen disease understanding.”
Continued evidence reinforcing the safety profile and efficacy of Ultomiris and Soliris
Two oral presentations will provide clinical and real-world evidence supporting the sustained long-term safety profile and efficacy of Ultomiris and Soliris in adults with the most common forms of NMOSD and gMG, respectively.
An interim analysis of the ongoing Phase III CHAMPION-NMOSD clinical trial will reinforce the potential for Ultomiris to prevent relapses in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) NMOSD. Data will demonstrate that zero patients treated with Ultomiris experienced an adjudicated relapse through a median follow-up of 170.3 weeks. In addition, most patients treated with Ultomiris were clinically stable or improved on disability measures through the longer-term follow-up highlighting the importance of preventing relapses to reduce disability decline in patients with NMOSD.
Results from a presentation spotlighting the three-year analysis from postmarketing surveillance (PMS) in Japan will show that treatment with Soliris demonstrated sustained effectiveness in patients with anti-acetylcholine receptor (AChR) antibody-positive (Ab+) gMG, regardless of Myasthenia Gravis Foundation of America (MGFA) classification, which is used to assess the severity of disease. Additionally, in an encore poster presentation, results from the first interim analysis from the Ultomiris gMG PMS in Japan will show that clinical effectiveness benefits were maintained in adult patients with AChR-Ab+ gMG who switched to Ultomiris from prior Soliris treatment.
Real-world data underscore benefit of C5 inhibitors in NMOSD and gMG clinical practice
A poster featuring real-world evidence from a global NMOSD registry will underscore the strong clinical benefit of Ultomiris and Soliris in relapse prevention in adults with AQP4-Ab+ NMOSD.
Global gMG registry findings will be shared in poster presentations, including real-world data demonstrating reduced oral corticosteroid burden in patients with AChR-Ab+ gMG receiving Soliris or Ultomiris and reduced hospitalisations, MG crises and exacerbations among patients with AChR-Ab+ gMG receiving Ultomiris.
Advancing understanding and innovation for the NMOSD and gMG communities
An oral presentation will share results of a study evaluating glial fibrillary acidic protein (GFAP) and Neurofilament Light Chain (NfL), biomarkers of astrocyte and neuronal injury, respectively, as potential indicators of disease activity in patients with AQP4-Ab+ NMOSD. In this analysis, high baseline GFAP and NfL levels in PREVENT and CHAMPION-NMOSD serum samples were associated with clinical characteristics related to age and ambulation. Data will show that no associations were observed between levels of these biomarkers and relapse risk or time to first adjudicated on-trial relapse.
A poster presentation will showcase preliminary results from Ad Scientiam’s decentralised research study, funded by Alexion, highlighting the potential clinical value of using the app-based tool, ME&MGopenTM, to collect digital data to track the daily impact of gMG symptoms in adults with AChR-Ab+ gMG, supporting its use in patient care.
Two poster presentations will feature ongoing clinical studies, including the study design for the Phase III, open-label, single-arm trial evaluating Ultomiris in paediatric patients with AChR-Ab+ gMG. Additionally, an encore poster will provide an overview of the ongoing Phase III PREVAIL trial assessing the safety profile and efficacy of gefurulimab, a novel, dual-binding nanobody, optimised for weekly subcutaneous administration, in adult patients with AChR-Ab+ gMG.
Further, results from Project ASPIRE (eliminAte diSparities and Promote equIty in Rare diseasE) will highlight health disparities among persons of colour (POC) who are living with gMG, underscoring the need for nationwide action plans to reduce barriers to healthcare and support for those who are disproportionally affected.
Alexion
Alexion, AstraZeneca Rare Disease is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and delivery of life-changing medicines. A pioneering leader in rare disease for more than three decades, Alexion was the first to translate the complex biology of the complement system into transformative medicines, and today it continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities. As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.